# Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

> **NCT05321810** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 193565 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT05321810
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-15
- **Primary completion:** 2022-04-15
- **Final completion:** 2022-04-15
- **Target enrollment:** 193565 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321810, "Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05321810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*